This PubMed/NCBI record cites a clinical-trial article in the New England Journal of Medicine (NEJM) titled "Survodutide Once Weekly for the Treatment of Adults with Obesity." The citation notes publication details: NEJM 2026;395(8):776-787, DOI 10.1056/NEJMoa2600751, with an electronic publication date listed as June 7, 2026, and a journal issue date of August 20, 2026.
The PubMed entry classifies the article as a clinical trial. The page provides the bibliographic metadata and a link to the NEJM/Atypon full-text hosting site.
The title of the record identifies the investigational agent as survodutide administered once weekly, and the intended clinical population as adults with obesity. Beyond the label "once weekly" in the title, the excerpted PubMed content available here does not provide additional protocol details such as dose escalation, specific dosing amount(s), duration of treatment, or comparator arms.
The PubMed record lists numerous named authors and a broad set of institutional affiliations. Lead and contributing authors include Carel W. le Roux and Sean Wharton among many others. Affiliations span academic institutions and clinical centers (for example, University College Dublin, McMaster University, Wake Forest School of Medicine, Baylor College of Medicine, University of Melbourne, Peking University People’s Hospital, Kobe University, University of Calgary, University of Helsinki, University of Glasgow, University Medical Center Groningen, KU Leuven, and more).
Several authors are affiliated with Boehringer Ingelheim (Boehringer Ingelheim International and Boehringer Ingelheim Pharma), indicating industry involvement in the study.
The record refers to a corporate author group, the SYNCHRONIZE-1 Investigators, and the collaborator list is extensive. The collaborator roster enumerates many individual site investigators and contributors from multiple countries, suggesting a multicenter, multinational trial infrastructure. The PubMed excerpt provided includes a partial list of these collaborators but is truncated in the available text.
The PubMed entry includes standard page features: navigation to Title & authors, Abstract, Similar articles, MeSH terms, and LinkOut resources. A full-text link is shown (Atypon/NEJM), and the page provides mechanisms to save or cite the article, add to collections, or email the citation. The PubMed interface elements (account, collections, citation export) are visible in the source excerpt but are not part of the study results.
The excerpted PubMed page reproduced here focuses on bibliographic information, author and collaborator listings, and the NEJM link. Crucially, the provided source text does not include the trial's methods, participant numbers, baseline characteristics, primary or secondary endpoints, statistical analyses, efficacy outcomes, safety or adverse-event results, or authors’ conclusions. Because these substantive trial details are not present in the available PubMed excerpt, they are not summarized or inferred here.
Where the PubMed snippet is silent, this rewrite does not supply missing data. Specifics such as the magnitude of weight loss, metabolic effects, adverse events, subgroup analyses, or regulatory implications were not reported in the provided source text and therefore cannot be asserted.
For clinicians, researchers, or guideline developers seeking actionable information on survodutide for obesity, consult the NEJM full-text article (link indicated on the PubMed page) to review the complete study design, enrollment criteria, intervention details (including exact dosing and treatment duration), primary and secondary outcomes, safety findings, statistical methods, and authors’ interpretation. The NEJM manuscript will also present tables, figures, and supplementary material that are necessary to assess clinical applicability and to inform practice or further research.
If access to the NEJM full text is restricted, consider institutional journal subscriptions, interlibrary loan, or contacting the corresponding author or sponsor for detailed study data. Additionally, trial registry entries (for example, ClinicalTrials.gov) may provide protocol summaries, prespecified endpoints, and timelines for the SYNCHRONIZE-1 trial, although those resources are not included in the PubMed excerpt provided here.
Summary
This PubMed citation documents a NEJM clinical-trial report of weekly survodutide for adults with obesity, authored by a large international group and associated with the SYNCHRONIZE-1 investigators. The PubMed excerpt supplies bibliographic and authorship information but does not include study results or detailed methods; readers must consult the NEJM full text or trial registry records for the complete trial data and clinical interpretation.